Recent News

• 04.22.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 04.08.2025 - Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
• 04.04.2025 - Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
• 04.01.2025 - Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
• 03.25.2025 - Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
• 03.05.2025 - Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
• 03.03.2025 - Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
• 02.26.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences

Recent Filings

• 04.01.2025 - 8-K Current report
• 04.01.2025 - EX-99.1 EX-99.1
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1
• 03.05.2025 - 8-K Current report
• 03.03.2025 - 8-K Current report
• 03.03.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities